Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife

We examined whether long-term exposure to visceral-adipose-tissue (VAT) influences brain atrophy and cognitive performance years after lifestyle intervention. In the Follow-Interventions-Trials (FIT) project, 533 adults (age=61.4 y, 86% men) from four prior 18-24-month lifestyle randomized-clinical-trials underwent abdominal/brain magnetic-resonance-imaging (MRI)s and Montreal-Cognitive-Assessment (MoCA) testing 5-16 y after interventions. Lower VAT exposure, calculated by area-under-the-curve, from baseline, post-intervention, and follow-up, independently resulted in higher MoCA scores. VAT loss during intervention predicted higher brain volumes at follow-up, independent of weight loss. Among participants with three brain and VAT MRI scans, lower long-term VAT was associated with a slower rate of brain atrophy. These patterns were not observed for deep/superficial subcutaneous-adipose-tissues. Improved glycemic control parameters, rather than lipid or inflammatory markers, were mostly related to the favorable longitudinal brain outcomes. This long-term, large-scale intervention and follow-up MRI study suggests that sustained visceral fat loss, rather than weight loss, is linked to better cognition and attenuation of brain atrophy years later, mainly via improved glycemic control. Trial registration: DIRECT (Clinical-trials-identifier: NCT00160108); CASCADE (Clinical-trials-identifier: NCT00784433); CENTRAL (Clinical-trials-identifier: NCT01530724); DIRECT-PLUS (Clinical-trials-identifier: NCT03020186).

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-03-26
DOI
https://doi.org/10.1038/s41467-026-71141-4
Primary Topic
Advanced Neuroimaging Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife

Iris Shai, Galia Avidan, Uri Yoel, Carmi Bartal et al.
Nature Communications
Advanced Neuroimaging Techniques and Applications
article

Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife

Iris Shai, Galia Avidan, Uri Yoel, Carmi Bartal, Assaf Rudich, Ilan Shelef, Hila Zelicha, M Stumvoll, ANAT YASKOLKA MEIR, Hadar Klein, Berend Isermann, Yoash Chassidim, Omer Kamer, Liav Alufer, Da‐Zhi Wang, Veronica Witte, Gal Ben-Arie, Dana Tamar Goldberg Toren, Dafna Pachter, Noa Ebstein Karamani, Meir J. Stampfer, Idan Hagbi, Moti Salti, Amit Yaary, Frank B. Hu, Tomer Atlas, Frauke Beyer, Matthias Blüher, Gal Tsaban, Lu Qi, Uta Ceglarek, Alon Kaplan
article en

Abstract

We examined whether long-term exposure to visceral-adipose-tissue (VAT) influences brain atrophy and cognitive performance years after lifestyle intervention. In the Follow-Interventions-Trials (FIT) project, 533 adults (age=61.4 y, 86% men) from four prior 18-24-month lifestyle randomized-clinical-trials underwent abdominal/brain magnetic-resonance-imaging (MRI)s and Montreal-Cognitive-Assessment (MoCA) testing 5-16 y after interventions. Lower VAT exposure, calculated by area-under-the-curve, from baseline, post-intervention, and follow-up, independently resulted in higher MoCA scores. VAT loss during intervention predicted higher brain volumes at follow-up, independent of weight loss. Among participants with three brain and VAT MRI scans, lower long-term VAT was associated with a slower rate of brain atrophy. These patterns were not observed for deep/superficial subcutaneous-adipose-tissues. Improved glycemic control parameters, rather than lipid or inflammatory markers, were mostly related to the favorable longitudinal brain outcomes. This long-term, large-scale intervention and follow-up MRI study suggests that sustained visceral fat loss, rather than weight loss, is linked to better cognition and attenuation of brain atrophy years later, mainly via improved glycemic control. Trial registration: DIRECT (Clinical-trials-identifier: NCT00160108); CASCADE (Clinical-trials-identifier: NCT00784433); CENTRAL (Clinical-trials-identifier: NCT01530724); DIRECT-PLUS (Clinical-trials-identifier: NCT03020186).

Nature Communications
Tulane University (US), Ben-Gurion University of the Negev (IL), Harvard University (US), Sapir College (IL), Soroka Medical Center (IL), Helmholtz Zentrum München (DE), Herzliya Medical Center (IL), Institute of Cognitive and Brain Sciences (US), University Hospital Leipzig (DE), Max Planck Institute for Human Cognitive and Brain Sciences (DE), Leipzig University (DE)
Good health and well-being
Openalex Percentile: Top 9%
Advanced Neuroimaging Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.